Health In TechvsJP Morgan Chase & Co.

HIT and JPM stock compared: price, dividend, valuation and results, from SEC filings.

Health In Tech (HIT) has a market value of $20M and JP Morgan Chase & Co. (JPM) $910B. Over the last year, with dividends, HIT moved -77.3% and JPM +13.3%. Dividend yield: HIT none, JPM 1.82%.

At a glance

The main figures of both. A bar only shows which number is larger, not which is better.

  • Market value

    HIT$20M

    JPM$910B

    JPM is 44,950 times HIT

  • Revenue, 12 months

    HIT$31M

    JPM$203B

    JPM is 6,569 times HIT

  • Net income, 12 months

    HIT-$11M

    JPM$66.0B

  • Operating margin

    HIT–

    JPM–

  • ROIC

    HIT-67.4%

    JPM15.1%

    82.5 points apart

  • P/E

    HIT–

    JPM14.1

  • Dividend yield

    HIT0.0%

    JPM1.8%

    1.8 points apart

A fainter bar means a negative number. The 5-year return includes dividends.

The price over time

Both start at 100 at the beginning of the period, so the lines show how much each changed. With dividends means each dividend buys more shares.

HIT-77.3%

JPM+13.3%

50100DecFebAprJunAugOct
Returns by period
PeriodHITWith dividendsJPMWith dividends
1 year since November 14, 2025-77.3%Price -77.3%+13.3%Price +11.1%

Each cell: the total return with dividends, its yearly rate, and the price change alone. Before taxes and costs. Past returns do not predict future ones.

Every figure

As on each company's page. A description, not a recommendation: no one figure says which is better.

HITHealth In TechJPMJP Morgan Chase & Co.

Valuation

HITJPM
Valuation
Price$0.36$337.48
Market value$20M$910B
Enterprise value (EV)$17M–
P/E–14.1
P/E, 5-year median–11.1
P/B1.62.6
EV/EBIT––
Free cash flow yield––

Results and growth

HITJPM
Results and growth
Revenue, 12 months$31M$203B
Net income, 12 months-$11M$66.0B
Free cash flow, 12 months––
Earnings per share, 12 months-$0.19$23.85
Revenue growth, year on year71.0%2.8%
Revenue growth a year, past+31.9%over 2 years+8.8%over 5 years
EPS growth a year, past+100.0%over 1 years+17.7%over 5 years

Margins and returns on capital

HITJPM
Margins and returns on capital
Gross margin50.5%–
Operating margin––
Net margin-37.1%32.5%
ROIC-67.4%15.1%
ROE-64.9%18.0%

Balance sheet

HITJPM
Balance sheet
Cash$10M$1.11T
Total debt$6.7M$531B
Net debt / EBITDA––
Interest cover––

Dividends and buybacks

HITJPM
Dividends and buybacks
Dividend yield–1.8%
Dividend per share, 12 months–$6.15
Dividend growth a year, past–+10.0%over 5 years
Buyback yield–3.5%
Shareholder yield–5.3%

Last 12 months from the latest 10-Q and 10-K. Value, P/E and yields at today's price. A dash means the figure does not exist or did not pass our checks.

Questions: HIT or JPM

Didn't find what you were looking for?

Ask us
Which is bigger, Health In Tech or JP Morgan Chase & Co.?

By market value, JP Morgan Chase & Co. ($910B) is about 44,950.2 times Health In Tech ($20M), at today's prices.

How did HIT and JPM stock do over the last 1 years?

Since November 14, 2025, HIT's price moved -77.3% and JPM's +11.1%. With dividends: HIT -77.3% (-77.3% a year), JPM +13.3% (+13.3% a year). Past returns do not predict future ones.

Which pays the higher dividend, HIT or JPM?

The dividend yield at today's price is none for Health In Tech and 1.82% for JP Morgan Chase & Co.. Over the last twelve months they paid – and $6.15 per share.

Which has the higher profit margins, Health In Tech or JP Morgan Chase & Co.?

Over the last twelve months, the net margin was -37.1% for Health In Tech and 32.5% for JP Morgan Chase & Co., and the operating margin – and –. Revenue was $31M and $203B.

Which is the better investment, Health In Tech or JP Morgan Chase & Co.?

The page does not answer that and does not suggest buying or selling. It puts the two companies' numbers side by side, from their SEC filings, for you to read and form your own view. The decision depends on your goals and situation.

Other comparisons

With each of the two, and with the largest in its sector.

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

Descriptive data from SEC filings and market prices.